SCHEMBL4579359

SCHEMBL4579359

O=C1CSC(=S)N1CCO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 8/20 0.59
GSK3B P49841 8/20 0.59
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
GAA P10253 4/20 0.58
ALDH1A1 P00352 5/20 0.49
RECQL P46063 4/20 0.47
MAPT P10636 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
POLB P06746 2/20 0.47
THRB P10828 2/20 0.47
HTT P42858 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
PAX8 Q06710 1/20 0.46
HSD17B10 Q99714 2/20 0.44
CYP1A2 P05177 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3062340 0.87 GSK3A (0.62) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL367565 0.83
SCHEMBL16636652 0.80 GSK3A (0.56) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL3138532 0.80 GSK3A (0.56) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL1279204 0.79 MEN1 (0.77) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL1693423 0.79 MAPT (0.56) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL4411450 0.78 GSK3A (0.53) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL17445529 0.78 MEN1 (0.60) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL2788487 0.77 MEN1 (0.59) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL3085058 0.77 KMT2A (0.88) GSK3AGSK3BMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649231-B2 Compound as mTOR inhibitor and use thereof MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2023-05-16 US disclosed
CN-113980858-A Lactobacillus plantarum YL399 for producing high-activity tannase and application thereof in preparation of codonopsis pilosula fermented feed 上海植酵盛生物科技有限公司 2022-01-28 CN disclosed
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2021-09-23 US disclosed
EP-3786163-A1 NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF Medicinal Bioconvergence Research Center (KR) 2021-03-03 EP disclosed
CN-112368279-A Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2021-02-12 CN disclosed
CN-1932644-B Method for producing sensitized dye and photosensitive composition given by using the same FUJI PHOTO FILM CO LTD 2010-05-12 CN disclosed
CN-101661223-A Photomask blank and photomask FUJI PHOTO FILM CO LTD 2010-03-03 CN disclosed
CN-100545751-C Photosensitive planographic plate FUJI PHOTO FILM CO LTD (JP) 2009-09-30 CN disclosed
CN-101526734-A Photo mask material, photo mask and photo mask preparing method FUJI PHOTO FILM CO LTD (JP) 2009-09-09 CN disclosed
EP-1688466-B1 Ink composition, ink jet recording method, printed material, method of producing planographic printing plate, and planographic printing plate FUJIFILM CORP (JP) 2008-11-26 EP disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
EP-0391644-B1 Aryl-substituted rhodanine derivatives LILLY CO ELI (US) 1996-06-19 EP disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
EP-0359431-B1 Halomethyl-1,3,5-triazines containing a sensitizer moiety MINNESOTA MINING & MFG (US) 1993-12-22 EP disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
US-4977076-A FLEXIBLE SUPPORT WITH SILVER HALIDE LIGHT SENSITIVE LAYER CONTAINING CYANINE DYE SENSITIZING AT SPECIFIC WAVELENGTHS FUJI PHOTO FILM CO., LTD. (JP) 1990-12-11 US disclosed
EP-0391644-A2 Aryl-substituted rhodanine derivatives ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed
EP-0359431-A2 Halomethyl-1,3,5-triazines containing a sensitizer moiety MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649231-B2 Compound as mTOR inhibitor and use thereof MTOR, RICTOR, RPTOR GSK3A 103/4885GSK3B 75/4885MEN1 855/4885
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MTOR, RICTOR, RPTOR GSK3A 143/4885GSK3B 110/4885MEN1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.